Patents by Inventor Eric J. Feldman

Eric J. Feldman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220265691
    Abstract: Cancer patients that express high levels of the E-selectin ligand (sialyl Lea/x) on their tumors have a poorer outcome. Interestingly, relapsed/refractory acute myeloid leukemia (AML) patients expressing high levels of sialyl Lex on their blasts show the greatest therapeutic response when treated with the E-selection inhibitor compound of Formula I. Transcriptome profiling of E-selectin ligand-forming glycosylation genes showed that ST3GAL4 and FUT7 were consistently expressed in the majority of cancers evaluated. Poor survival outcomes of FLT3-mutated AML patients that express high levels of ST3GAL4 and FUT7 implicated E-selectin in this disease state. These genes may be predictive biomarkers in AML patients. Methods of treatment of cancer comprising screening AML patients for expression of genes that contribute to the synthesis of the E-selectin ligand sialyl Lex, then treating those patients with an E-selection inhibitor, are disclosed.
    Type: Application
    Filed: July 12, 2020
    Publication date: August 25, 2022
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. MAGNANI, William E. FOGLER, Helen M. THACKRAY, Eric J. FELDMAN, David STEWART
  • Publication number: 20190117787
    Abstract: This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with hypomethylating agents.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 25, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Dana Kennedy, Megan O'Meara, Eric J. Feldman